Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Therapeutic approaches in sickle cell disease].
Joseph L, Arlet JB, Bernaudin F, Dhédin N. Joseph L, et al. Among authors: dhedin n. Rev Prat. 2023 May;73(5):535-539. Rev Prat. 2023. PMID: 37309792 French.
Recent results of hematopoietic stem cell transplantation for thalassemia with busulfan-based conditioning regimen in France: improved thalassemia free survival despite frequent mixed chimerism. A retrospective study from the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC).
Rossi M, Szepetowski S, Yakouben K, Paillard C, Sirvent A, Castelle M, Pegon C, Piguet C, Grain A, Angoso M, Robin M, Dhedin N, Pondarré C, Dumesnil de Maricourt C, Berceanu A, Simon P, Marcais A, Poirée M, Gandemer V, Plantaz D, Nguyen S, Michel G, Loundou A, Dalle JH, Thuret I. Rossi M, et al. Among authors: dhedin n. Bone Marrow Transplant. 2023 Nov;58(11):1254-1256. doi: 10.1038/s41409-023-02079-0. Epub 2023 Aug 4. Bone Marrow Transplant. 2023. PMID: 37542188 No abstract available.
All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial.
Belhabri A, Thomas X, Wattel E, Chelghoum Y, Anglaret B, Vekhoff A, Reman O, Dombret H, Dhedin N, Michallet M, Fière D, Archimbaud E. Belhabri A, et al. Among authors: dhedin n. Hematol J. 2002;3(1):49-55. doi: 10.1038/sj.thj.6200141. Hematol J. 2002. PMID: 11960396 Clinical Trial.
Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial.
Cordonnier C, Chevret S, Legrand M, Rafi H, Dhédin N, Lehmann B, Bassompierre F, Gluckman E; GREFIG Study Group. Cordonnier C, et al. Among authors: dhedin n. Ann Intern Med. 2003 Jul 1;139(1):8-18. doi: 10.7326/0003-4819-139-1-200307010-00007. Ann Intern Med. 2003. PMID: 12834313 Clinical Trial.
154 results